Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8227151 | 0.85 | CA1 (0.50) | SMN1; SMN2NR1H4CA1CA2EPHX2 | |
| SCHEMBL5692310 | 0.83 | ALDH1A1 (0.44) | SMN1; SMN2CA1CA2CA12NPC1 | |
| SCHEMBL12622715 | 0.83 | VDR (0.50) | SMN1; SMN2NR1H4CA1CA2EPHX2 | |
| SCHEMBL2054679 | 0.81 | POLB (0.58) | SMN1; SMN2NR1H4CA1CA2EPHX2 | |
| SCHEMBL28326346 | 0.81 | CA1 (0.48) | SMN1; SMN2NR1H4CA1CA2EPHX2 | |
| SCHEMBL28493929 | 0.81 | LMNA (0.55) | SMN1; SMN2NR1H4CA1CA2EPHX2 | |
| SCHEMBL951015 | 0.81 | FFAR1 (0.58) | CA1CA2EPHX2CA12CA7 | |
| SCHEMBL14065404 | 0.79 | HDAC8 (0.50) | NR1H4CA1CA2CA12HDAC3 | |
| SCHEMBL5958669 | 0.78 | FFAR1 (0.44) | SMN1; SMN2CA1CA2EPHX2CA12 | |
| SCHEMBL498570 | 0.78 | ALDH1A1 (0.54) | SMN1; SMN2CA1CA2CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113480485-B | 1,2, 4-triaryl-1, 2, 4-triazoles compound and synthetic method thereof | 甘肃农业大学 | 2023-04-07 | — | — | CN | claimed |
| CN-117362188-B | Synthesis method of alpha-substituted deuterated amino acid ester | 广州医科大学 | 2025-05-20 | — | — | CN | disclosed |
| CN-117362188-A | Synthesis method of alpha-substituted deuterated amino acid ester | 广州医科大学 | 2024-01-09 | — | — | CN | disclosed |
| CN-113480485-B | 1,2, 4-triaryl-1, 2, 4-triazoles compound and synthetic method thereof | 甘肃农业大学 | 2023-04-07 | — | — | CN | disclosed |
| US-20210121465-A1 | FERROCHELATASE INHIBITORS AND METHODS OF USE | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2021-04-29 | — | — | US | disclosed |
| EP-3787630-A1 | FERROCHELATASE INHIBITORS AND METHODS OF USE | Indiana University Research and Technology Corporation (US) | 2021-03-10 | — | — | EP | disclosed |
| WO-2016086015-A1 | MYOGLOBIN-BASED CATALYSTS FOR CARBENE TRANSFER REACTIONS | UNIVERSITY OF ROCHESTER (US) | 2016-06-02 | — | — | WO | disclosed |
| EP-1542667-B1 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-1542667-A2 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004009558-A2 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS, THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASES CAUSED BY SUCH MUTATIONS | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121465-A1 | FERROCHELATASE INHIBITORS AND METHODS OF USE | FECH, SLC40A1, TPI1 | SMN1; SMN2 2465/4885NR1H4 1311/4885CA1 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.